| All Releases |
|---|
 |
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Jun 22, 2009
|
14.8 KB
|
| |
CRANBURY, N.J., June 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S. Food and Dru...
|
|
|
Amicus Therapeutics Announces First Quarter 2009 Financial Results
May 7, 2009
|
19.9 KB
|
| |
CRANBURY, N.J., May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the first quarter 2009.
On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0....
|
|
|
Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
Apr 30, 2009
|
8.2 KB
|
| |
CRANBURY, N.J., April 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce first quarter 2009 financial results after the regular close of markets on Thursday, May 7, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.
Interested ...
|
|
|
Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Mar 30, 2009
|
7.6 KB
|
| |
CRANBURY, N.J., March 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming 16th Annual Future Leaders in the Biotech Industry conference at New York City's Millennium Broadway Hotel and Confer...
|
|
|
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Mar 28, 2009
|
12.7 KB
|
| |
CRANBURY, N.J., March 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal(TM) (migalastat HCL) for Fabry disease. The results will be presented at the American College of Medical Genetics (ACMG) 20...
|
|
|
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Mar 25, 2009
|
9.8 KB
|
| |
CRANBURY, N.J., March 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Com...
|
|
|
Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Mar 11, 2009
|
7.6 KB
|
| |
CRANBURY, N.J., March 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's President and Chief Executive Officer John F. Crowley will be presenting at the upcoming Cowen and Company 29th Annual Healthcare Conference. Mr. Crowley's presentation is scheduled to begin on Tues...
|
|
|
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Feb 27, 2009
|
12.2 KB
|
| |
CRANBURY, N.J., Feb 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S....
|
|
|
Amicus Therapeutics Announces Change to Board of Directors
Feb 18, 2009
|
7.0 KB
|
| |
CRANBURY, N.J., Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that Stephen Bloch, M.D., General Partner with Canaan Equity Partners, has resigned from the Company's Board of Directors effective February 17, 2009. Dr. Bloch served as a member of Amicus' board since 2004.
About Ami...
|
|
|
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Feb 5, 2009
|
23.9 KB
|
| |
CRANBURY, N.J., Feb 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Company Advancing Core Lysosomal Storage Disorder Programs to Key Milestones in 2009; Expects Continued Strong Financial Position
Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2008.
On a reported basis calcula...
|
|
|
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Jan 29, 2009
|
8.3 KB
|
| |
CRANBURY, N.J., Jan 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m....
|
|
|
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Jan 12, 2009
|
14.1 KB
|
| |
CRANBURY, N.J., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position
Amicus Therapeutics (Nasdaq: FOLD) today announced positive progress in its three lead clini...
|
|
|
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Jan 8, 2009
|
7.7 KB
|
| |
CRANBURY, N.J., Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr. Barer brings over 20 years of manag...
|
|
|
Amicus Therapeutics to Present at J.P. Morgan Healthcare Conference
Dec 22, 2008
|
10.1 KB
|
| |
CRANBURY, N.J., Dec 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics
(Nasdaq: FOLD) today announced that its President & CEO John F. Crowley will
present a corporate overview and the Company's 2009 key business objectives at
the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009,
at 11:30 a.m...
|
|
|
Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
Nov 11, 2008
|
8.2 KB
|
| |
CRANBURY, N.J., Nov 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced President and CEO, John F. Crowley, will make a presentation at the 5th Annual Lazard Capital Markets Healthcare Conference in New York on Tuesday, November 18, 2008, at 5:10 p.m. EST.
A webcast and audio archive of...
|
|
|
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Nov 3, 2008
|
22.2 KB
|
| |
CRANBURY, N.J., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of ...
|
|
|
Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Oct 27, 2008
|
8.6 KB
|
| |
CRANBURY, N.J., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce third quarter 2008 financial results after the regular close of markets on Monday, November 3, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. ET.
Interest...
|
|
|
Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Sep 17, 2008
|
7.9 KB
|
| |
CRANBURY, N.J., Sept 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced that President and Chief Executive Officer John F. Crowley will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 10:30 a.m. EDT in New York.
An audio webcast of th...
|
|
|
Amicus Therapeutics Opens Research Facility in San Diego
Sep 15, 2008
|
10.1 KB
|
| |
CRANBURY, N.J. and SAN DIEGO, Sept 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focuse...
|
|
|
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Aug 29, 2008
|
8.0 KB
|
| |
CRANBURY, N.J., Aug 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced Chief Operating Officer Matthew Patterson will make a presentation at the BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:30 p.m. EDT in Room 402/403 with a breakout session ...
|
|
|
Shareholder Briefcase
Investor Kit
News & Event Alerts
Download Library
News Feeds
